Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background: Clinical diagnosis of Alzheimer’s disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer’s disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing–Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland–Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan–Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815−27). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · cited 1×
“To increase the certainty of AD being the underlying cause of dementia, several AD diagnostic criteria recommend the use of biomarkers tightly associated with AD pathology hallmarks [3,4].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“7% had intermediate or high probability of AD pathology according to the NIA-AA neuropathological guidelines [22] (data not published).”
MethodJessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 16×
“However, these SCD individuals were participants of the FACEHBI study, with normal cognitive testing, and who had been cognitively stable over the three years after PET evaluation.”
MethodInfluentialCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Extracellular amyloid plaques, mainly formed by Aβ1-42 peptide, and intraneuronal neurofibrillary tangles, formed by phosphorylated Tau protein aggregates, are, along with cerebral amyloid angiopathy (CAA) and subsequent neuronal loss, the main neuropathological hallmarks of Alzheimer’s disease (AD) [1,2].”
BackgroundCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
MULTI-INFARCT DEMENTIA A CAUSE OF MENTAL DETERIORATION IN THE ELDERLY
HACHINSKI, V (1974) · The Lancet · doi:10.1016/s0140-6736(74)91496-2 · Cited by 1,093
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808
Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358
del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22491-8 · Cited by 324
Self-citationCerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.013 · Cited by 284
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183 · cited 4×
“However, Aβ1-40 improved the agreement with amyloid PET visual status [14,28,29] and can be instrumental in the normalization of Aβ1-42, introducing the inter-individual variation in the total amyloid load [30].”
BackgroundMethodInfluentialSelf-citationJanelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147 · cited 1×
“However, Aβ1-40 improved the agreement with amyloid PET visual status [14,28,29] and can be instrumental in the normalization of Aβ1-42, introducing the inter-individual variation in the total amyloid load [30].”
BackgroundHansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136 · cited 2×
“The widespread application of these protocols will help to minimize variability in measurements and to facilitate the implementation of unified cutoff levels across laboratories using the same platform [11].”
BackgroundLacour, A., Espinosa, A., Louwersheimer, E., Heilmann, S., Hernández, I., Wolfsgruber, S., Fernández, V, Wagner, H., Rosende-Roca, M., Mauleón, A., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.18 · Cited by 101
Self-citationde Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2019) · doi:10.1101/19012021 · Cited by 28
Self-citation
Cited by
Cruchaga, C., Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Ali, M., Beric, A., Gorijala, P., Kohlfeld, P., et al. (2023) · doi:10.21203/rs.3.rs-2814616/v1 · Cited by 112
Self-citationWestern, D., Timsina, J., Wang, L., Wang, C., Yang, C., Phillips, B., Wang, Y., Liu, M., Ali, M., Beric, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01972-8 · Cited by 111
Self-citationMorató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
“The CSF Aβ42 levels for control groups are ≈900 pg/mL and the plasma Aβ42 levels assayed with IMR are ≈15 pg/mL [40,41].”
BackgroundSelf-citationSerum proteomics reveals APOE dependent and independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jonmundsson, T., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A., Boada, M., et al. (2023) · doi:10.1101/2023.11.08.23298251 · Cited by 3
Self-citation
Metadata
- Authors
- Orellana, A., García-González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende-Roca, M., Vargas, L., Tartari, J. P., Esteban-De Antonio, E., Bojaryn, U., Narvaiza, L., Alarcón-Martín, E., Alegret, M., Alcolea, D., Lleó, A., Tárraga, L., Pytel, V., Cano, A., Marquié, M., Boada, M., & Ruiz, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-06-21
- Volume
- 23
- Issue
- 13
- Pages
- 6891
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4283266263
- Cited by
- 59
- References
- 20
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.